%0 Journal Article
%T Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer
%A Shigeto Ueda
%A Nobuo Kondoh
%A Hitoshi Tsuda
%A Souhei Yamamoto
%A Hideki Asakawa
%A Kazuhiko Fukatsu
%A Takayuki Kobayashi
%A Junji Yamamoto
%A Katsumi Tamura
%A Jiro Ishida
%A Yoshiyuki Abe
%A Mikio Yamamoto
%A Hidetaka Mochizuki
%J BMC Cancer
%D 2008
%I BioMed Central
%R 10.1186/1471-2407-8-384
%X We compared mRNA expression profiles between 14 tumors with low SUVs and 24 tumors with high SUVs by cDNA microarray. We identified centromere protein F (CENP-F) and CDC6 were upregulated in tumors with high SUVs. RT-PCR and immunohistochemical analyses were performed to validate these data. Clinical implication of CENP-F and CDC6 was examined for 253 archival breast cancers by the tissue microarray.The relative ratios of CENP-F and CDC6 expression levels to ¦Â-actin were confirmed to be significantly higher in high SUV tumors than in low SUV tumors (p = 0.027 and 0.025, respectively) by RT-PCR. In immunohistochemical analysis of 47 node-negative tumors, the CENP-F expression was significantly higher in the high SUV tumors (74%) than the low SUV tumors (45%) (p = 0.04), but membranous and cytoplasmic CDC6 expressions did not significantly differ between both groups (p = 0.9 each). By the tissue microarray, CENP-F (HR = 2.94) as well as tumor size (HR = 4.49), nodal positivity (HR = 4.1), and Ki67 (HR = 2.05) showed independent impact on the patients' prognosis.High CENP-F expression, correlated with high SUV, was the prognostic indicators of primary breast cancer. Tumoral SUV levels may serve as a pretherapeutic indicator of aggressiveness of breast cancer.Although a majority of patients with primary breast cancer are cured by locoregional treatment with or without systemic therapy, approximately 10¨C30% of these patients experience recurrence of the cancer [1]. Researchers have suggested various biomarkers or risk categories of breast cancer to reliably identify high-risk patients, who would require chemotherapy, and low-risk patients, who can be treated without chemotherapy [2]. Nodal status is the important prognostic and predictive factors in the treatment of primary breast cancer; however, there are still no definitive criteria that can identify high-risk patients with primary breast cancer, especially those with node-negative (pN0) breast cancer.Currently, prima
%U http://www.biomedcentral.com/1471-2407/8/384